[Radioimmunoassay for prostatic acid phosphatase in human serum. Methodologic aspects (author's transl)].
We propose a double antibody radioimmunoassay for human prostatic acid phosphatase (PAP) in serum for diagnosis and management of prostatic adenocarcinoma under treatment. The antigen is purified from human prostatic fluid by a gel-filtration on Sephadex G 100 followed by affinity chromatography on Con A Sepharose. A specific antibody is raised in rabbits and purified by immunoadsorption with a female serum. The described technique offers both radioisotopic sensibility and immunologic specificity. Physiological values determined in the serum of 125 healthy males are below 2 ng/ml. No significative differences are observed with age. The proposed technique also shows significant differences between values evaluated for benign prostatic hyperplasia and prostatic adenocarcinoma.
D000135:Acid Phosphatase / Q000097:blood*; D006801:Humans; D008297:Male; D011379:Prognosis; D011467:Prostate / Q000201:enzymology*; D011471:Prostatic Neoplasms / Q000201:enzymology*; D011863:Radioimmunoassay / Q000379:methods; D012016:Reference Values
D000135:Acid Phosphatase
Dosage radio-immunologique de la phosphatase acide prostatique du sérum. Aspects méthodologiques.